Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoCOAST-2: Neoadjuvant and Adjuvant Treatment in Resectable, Early-stage Non-small Cell Lung Cancer
NCT05061550Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Primary completion
- May 2030
- Modality
- Prophylactic Vaccines, Small Molecules, Bispecific Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of oleclumab, monalizumab, volrustomig, datopotamab deruxtecan, AZD0171 and 1 more in non-small cell lung cancer (NSCLC) (7 arms), sponsored by AstraZeneca. Primary endpoints: Pathological Complete Response at 15 weeks and Adverse Events and Serious Adverse Events up to 3 years. Started Apr 2022; status: recruiting.
02
Drugs
oleclumabmonalizumabvolrustomigdatopotamab deruxtecanAZD0171
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05061550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061550.